Viridian Therapeutics, Inc. (VRDN) earnings
VRDN earnings moved a median of +2.37% by the close. Quarterly and annual VRDN reports and results, each read against the price at its own news timestamp. Back to the VRDN overview →
22 measured VRDN earnings events.
Where these VRDN earnings landedvs 22 measured VRDN earnings reactions
| Middle 50% of VRDN earnings reactions | -3.93% to +4.07% |
|---|---|
| Median reaction (to close) | +2.37% |
| Measured reactions | 22 |
Point-in-time · zero look-ahead
Half of the 22 VRDN earnings events with a measured close landed between -3.93% and +4.07%; 59% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Viridian Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +2.05% | +9.64% | |
| Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results | Press release | +2.05% | +9.64% | |
| Form 10-Q Viridian Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +1.51% | +1.41% | |
| Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress | Press release | +1.51% | +1.41% | |
| Form 10-K Viridian Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +0.33% | +9.02% | |
| Form 10-Q Viridian Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +0.17% | +4.99% | |
| Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress | Press release | +0.17% | +4.99% | |
| Form 10-Q Viridian Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -2.17% | -3.04% | |
| Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results | Press release | -2.17% | -3.04% | |
| Form 10-Q Viridian Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +0.04% | -7.03% | |
| Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results | Press release | +0.04% | -7.03% | |
| Form 10-K Viridian Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +0.26% | -7.63% | |
| Form 10-Q Viridian Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -6.73% | -17.05% | |
| Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data | Press release | -6.73% | -17.05% | |
| Form 10-Q Viridian Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +1.30% | +3.35% | |
| Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results | Press release | +1.30% | +3.35% | |
| Form 10-Q Viridian Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -2.00% | -3.93% | |
| Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results | Press release | -2.00% | -3.93% | |
| Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024 | Press release | -0.69% | +4.29% | |
| Form 10-K Viridian Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +2.74% | +3.33% | |
| Form 10-Q Viridian Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +1.50% | +3.40% | |
| Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update | Press release | +1.50% | +3.40% |
Keep exploring
More VRDN: analyst actions → · SEC filings → · VRDN overview →